BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...Corp. spun out Antengene Corp. with Chinese and Taiwanese rights to mTORC1 and mTORC2 inhibitor CC-223...
BioCentury | Jan 4, 2019
Financial News

China's Antengene raises $120M series B round

...round on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008...
...Inc. (NASDAQ:KPTI) in May (see "Antengene Adds Bundle of Karyopharm Assets to Pipeline" ). ATG-008 (CC-223...
BioCentury | Jan 2, 2019
Financial News

China's Antengene raises $120M series B round

...million series B round to fund development of its two lead cancer compounds, selinexor and ATG-008...
...Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in May (see "Antengene Fills Pipeline with Karyopharm Deal" ). ATG-008 (CC-223...
BioCentury | May 25, 2018
Company News

Antengene adds bundle of Karyopharm assets to pipeline

...I testing for advanced solid tumors and non-Hodgkin's lymphoma (NHL). Last year, Antengene acquired ATG-008 (CC-223...
...Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Newton, Mass. Antengene Corp., Shanghai, China Business: Cancer Allison Johnson KPT-8602 KPT-9274 selinexor (KPT-330) TORKi (ATG-008, CC-223) Antengene...
BioCentury | May 24, 2018
Company News

Antengene fills pipeline with Karyopharm deal

...I testing for advanced solid tumors and non-Hodgkin's lymphoma (NHL). Last year, Antengene acquired ATG-008 (CC-223...
...BioCentury, Aug. 18, 2017) . Karyopharm slipped $1.72 to $17.34 on Thursday. Allison Johnson KPT-8602 KPT-9274 selinexor (KPT-330) TORKi (ATG-008, CC-223) Antengene...
BioCentury | Aug 18, 2017
Finance

Ante Antengene

...registrational studies for both drugs. Antengene’s first asset, in-licensed from Celgene in April, is ATG-008 (CC-223...
...term, the company plans to partner with companies and academics on preclinical compounds. Virginia Li, Staff Writer ATG-008 Antengene...
BioCentury | Aug 18, 2017
Financial News

Antengene raises $21M series A

...participation by TF Capital, HG Capital and Tigermed Investment. Antengene has exclusive rights to ATG-008 (CC-223...
...director of clinical development in hematology and oncology at Celgene. Antengene Corp. , Shanghai, China Kevin Lehnbeuter ATG-008 CC-223 Antengene...
BioCentury | Aug 16, 2017
Financial News

Antengene raises $21M series A

...participation by TF Capital, HG Capital and Tigermed Investment. Antengene has exclusive rights to ATG-008 (CC-223...
...Mei was an executive director of clinical development in hematology and oncology at Celgene. Virginia Li Antengene Corp.CC-223Mammalian...
BioCentury | Jul 7, 2017
Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

...company earlier this year. In April, the company granted Antengene Corp. (Shanghai, China) rights to CC-223...
...kinase (see BioCentury Extra, April 18) . Celgene slipped $1.25 to $131.95 on Thursday. Jaime De Leon ABI-007 Abraxane azacitidine BGB-A317 CC-122 CC-5013 lenalidomide nab-paclitaxel NS-17 Revlimid TORKi Vidaza Antengene...
BioCentury | Apr 21, 2017
Company News

Celgene, Antengene deal

...Antengene gained rights in Taiwan and China, including Hong Kong and Macau, to oncology candidate CC-223...
...and took a board seat. Antengene will be responsible for local development and commercialization of CC-223...
...cancer (NSCLC) patients. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Antengene Corp. , Shanghai, China Business: Cancer Shannon Lehnbeuter CC-223 Celgene...
Items per page:
1 - 10 of 11